Decrypting cryptogenic hepatocellular carcinoma: Clinical manifestations, prognostic factors and long-term survival by propensity score model

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Hsu, Chia Yang ^a,b,c   Lee, Yun Hsuan ^a,b   Liu, Po Hong ^a,b   Hsia, Cheng Yuan ^a,b   Huang, Yi Hsiang ^a,b   Lin, Han Chieh ^a,b   Chiou, Yi You ^a,b   Lee, Fa Yauh ^a,b   Huo, Teh Ia ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT;

ABDOMINAL DISCOMFORT; ADULT; ADVANCED CANCER; ALCOHOLISM; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FUNCTIONAL STATUS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN TISSUE; INCIDENTAL FINDING; KIDNEY DYSFUNCTION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTION; PROPENSITY SCORE; PROSPECTIVE STUDY; REFERENCE VALUE; STATISTICAL MODEL; SURVIVAL TIME; TUMOR INVASION; AGED; LIVER TUMOR; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84897901717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089373     Document Type: Article

References (36)

1. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology134: 1752-1763. (Pubitemid 351615415)
2. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, et al. (2010) Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 116: 3006-3014.
3. Tsai YJ, Hsu CY, Huang YH, Su CW, Lin HC, et al. (2011) Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int 5: 975-984.
4. Pekow JR, Bhan AK, Zheng H, Chung RT (2007) Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 109: 2490-2496. (Pubitemid 46908652)
5. Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37: 1202-1219. (Pubitemid 36538699)
6. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, et al. (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42: 44-52. (Pubitemid 40911310)
7. Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, et al. (2013) Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma. BMC Cancer 13: 335.
8. Chang CH, Lin JW, Wu LC, Liu CH, Lai MS (2013) National antiviral treatment program and the incidence of hepatocellular carcinoma and associated mortality in Taiwan: a preliminary report. Med Care 51: 908-913.
9. Yeh YP, Hu TH, Cho PY, Chen HH, Yen AM, et al. (2013) Evaluation of abdominal ultrasonography mass screening for hepatocellular carcinoma in Taiwan. Hepatology (in press). doi: 10.1002/hep.26703.
10. Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S (2011) Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol 46: 1230-1237.
11. Yokoi Y, Suzuki S, Baba S, Inaba K, Konno H, et al. (2005) Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection. J Gastroenterol 40: 274-282. (Pubitemid 40613385)
12. Lee YH, Hsu CY, Huang YH, Su CW, Lin HC, et al. (2013) Alpha-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma. J Gastrointest Surg 17: 730-738.
13. Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, et al. (2012) A prognostic model for patients with hepatocellular carcinoma within the Milan criteria undergoing non-transplant therapies, based on 1106 patients. Aliment Pharmacol Ther 36: 551-559.
14. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430. (Pubitemid 32844200)
15. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42: 1208-1236. (Pubitemid 43112690)
16. Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, et al. (2013) Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int 7: 645-654.
17. Hsu CY, Lee YH, Huang YH, Hsia CY, Su CW, et al. (2013) Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy. Hepatol Int 7: 188-198.
18. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, et al. (2013) Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system. Hepatology 57: 112-119.
19. Lee YH, Hsu CY, Huang YH, Su CW, Lin HC et al. (2012) Selecting a prognostic renal surrogate for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol 27: 1581-1588.
20. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, et al. (2010) A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 53: 108-117.
21. Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, et al. (2013) Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One 8: e80276.
22. Lee S, Kim BK, Kim SU, Park Y, Chang S, et al. (2013) Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PloS One 8: e77240.
23. Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, et al. (2013) Performance status enhances the selection of treatment for patients with hepatocellular carcinoma within the milan criteria. Ann Surg Oncol 20: 2035-2042.
24. Austin PC (2013) A comparison of 12 algorithms for matching on the propensity score. Stat Med (in press). doi: 10.1002/sim.6004.
25. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, et al. (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128: 2436-2443.
26. Gellert L, Jalaludin B, Levy M (2007) Hepatocellular carcinoma in Sydney South West: late symptomatic presentation and poor outcome for most. Intern Med J 37: 516-522. (Pubitemid 47084172)
27. Lee CS, Sung JL, Hwang LY, Sheu JC, Chen DS, et al. (1986) Surgical treatment of 109 patients with symptomatic and asymptomatic hepatocellular carcinoma. Surgery 99: 481-490.
28. Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, et al. (2014) Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. J Med Virol 86: 131-138.
29. Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, et al. (2013) Factors that Affect Accuracy of alpha-Fetoprotein Test in Detection of Hepatocellular Carcinoma in Patients with Cirrhosis. Clin Gastroenterol Hepatol (in press). doi: 10.1016/j.cgh.2013.09.053.
30. Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, et al. (2012) Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 55: 1809-1819.
31. Caldwell SH, Crespo DM (2004) The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 40: 578-584. (Pubitemid 38367778)
32. Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35: 519-524. (Pubitemid 34183954)
33. Kao WY, Su CW, Chau GY, Lui WY, Wu CW, et al. (2011) A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg 35: 858-867.
34. Tokushige K, Hashimoto E, Yatsuji S, Tobari M, Taniai M, et al. (2010) Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol 45: 960-967.
35. Kudo M (2011) Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology 81 Suppl 1: 50-55.
36. Kubo S, Takemura S, Sakata C, Urata Y, Uenishi T (2013) Adjuvant Therapy after Curative Resection for Hepatocellular Carcinoma Associated with Hepatitis Virus. Liver Cancer 2: 40-46.